Cudetaxestat is under clinical development by Blade Therapeutics and currently in Phase I for Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease). According to GlobalData, Phase I drugs for Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease) have a 100% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Cudetaxestat’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Cudetaxestat overview

Cudetaxestat is under development for the treatment of non-alcoholic steatohepatitis (NASH), systemic sclerosis, interstitial lung diseases, Liver Fibrosis, Lung Fibrosis and idiopathic pulmonary fibrosis. The therapeutic candidate is administered through oral route as a solution. The drug candidate acts by targeting autotaxin (ATX).

It was also under development for the treatment of kidney fibrosis and inflammatory bowel disease (IBD).

Blade Therapeutics overview

Blade Therapeutics is a biopharmaceutical company. The company’s products pipeline includes Cudetaxestat, BLD-2184, BLD-3051, autotaxin inhibitor, and calpin inhibitor. It develops novel anti-fibrotic therapies to treat various fibrotic disorders and it’s lead program is a small molecule inhibitor targeting an intracellular cysteine protease associated with fibrosis across diverse indications. The company conducts research and development programs to discover new drugs that modulate fibrosis-related diseases such as idiopathic pulmonary fibrosis (IPF), non-alcoholic steatohepatitis (NASH), viral hepatitis, ALD and cirrhosis. It works in partnership with Scleroderma Research Foundation (SRF) to treat disorders of fibrosis, including scleroderma. Blade Therapeutics is headquartered in San Francisco, California, the US.

For a complete picture of Cudetaxestat’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 2 September 2023

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.